summari host bi-annu pharma investor day may
expect highlight robust in-market portfolio
late-stag pipelin help return pharmaceut
busi above-market growth pharma sale
growth expect trail market due impact
gener zytiga tracleer biosimilar eros continu
growth key franchis increas contribut new
product deliv mid- high-singl digit pharma sale
growth come year see pharma investor day
import opportun highlight growth opportun
increas investor confid busi outperform
market share under-perform peer
 ytd due neg sentiment talc litig
soft sale growth expect pharma overal sale
growth improv acceler meaning
driven stronger perform three busi
forecast organ sale growth pharma overal
respect
rais price target increas
price target base updat sotp sum-
of-the-part analysi assum consum trade
discount peer pharma trade premium
peer medic devic trade discount peer
price target repres ep estim
stock trade ep close
averag price-to-earnings share trade discount
compar averag premium
neg sentiment weigh share ytd share
vs reflect neg investor
sentiment around talc litig depress sale growth
due pharma headwind provid updat talc
litig note see risk manag top-
line growth improv continu next year
expect overal sale growth acceler driven
improv three unit includ pharma growth increas
year figur move
expect investor turn focu growth acceler
improv sentiment drive multipl expans
pharma sale estim exce consensu
five key drug bullish
darzalex stelara invega sustenna/trinza franchis imbruvica
prezista
street may
underestim growth opportun drug
continu next page
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
compani data secur llc estim reuter
continu previou page
pharma event drive futur growth expect may pharma busi review
import provid greater visibl jnj pipelin boost investor confid
pharma busi return above-the-market growth event pharma rest
includ fda approv darzalex front-lin multipl myeloma base maia data
critic move darzalex treatment part backbon therapi stelara approv
ulcer coliti us/eu togeth crohn help sustain drug growth
momentum file darzalex subcutan subq formul multipl myeloma mm
transplant indic us/eu approv expand patient access
address patient popul file data present spravato suicid prevent
approv fuel uptak believ mileston provid sever new growth
driver jnj pharma busi beyond
figur overal sale growth acceler
organ organ report adjust fx acquisitions/divestitur adjust us sell day differ hep-c franchis disclos prior period price adjust ppa secur llc estimatessales/growthsal cagrpotenti approv us/euerleada apalutamid non-metastat prostat cancer eu janmetastat castrat sensit prostat cancer titan us year-endbalversa erdafitinib urotheli cancer us aprspravato esketamin nasal spray treatment-resist depress us eu ulcer coliti us eu vte prevent medic ill patient us octimbruvica frontlin cll combo w/obinutuzumab us jan eu waldenstrm macroglobulinemia combo w/rituximab eu patient-control injector us febdarzalex front-lin multipl myeloma w/ lenalidomid low dose dexamethason maia us submiss us/eurilpivirin cabotegravir long actinghiv mainten us apr euspravato esketamin nasal spray major depress disord immin risk suicid us darzalex front-lin multipl myeloma w/ lenalidomid low dose dexamethason maia us eu frontlin multipl myeloma transplant cassopeia us eu subq mulat relapsed/refractori multipl myeloma columba us eu apalutamid metastat castrat sensit prostat cancer titan us apr euinvokanatreat ckd type diabet patient us eutremfya psoriat arthriti us eu potenti clinic data presentationsinvokanatreat ckd type diabet credenc apr world congress nephrolog stelara ulcer coliti unifi rilpivirin cabotegravir long actinghiv mainten atla flair croi tremfyapsoriat arthriti discov apalutamid metastat castrat sensit prostat cancer titan may asco spravato esketamin major depress disord immin risk suicid ii darzalex subq mulat patient w/ relapsed/refractori multipl myeloma columba frontlin multipl myeloma transplant cassopeia uptravi pulmonari arteri hypertens iv pulmonari arteri hypertens griphon compani report secur llcphase johnson johnson
market growth like still mid-single-digit rang pharma day
note im estim global brand pharmaceut market grow compound-annual-growth-rate
expect peg overal market growth next year similar rang perhap
touch lower given increas price pressur base consensu estim large-cap
global pharmaceut compani ex-jnj sale compound-annual-growth-rate expect us-
base compani compar period figur forecast jnj pharma sale
compound-annual-growth-rate slightli still global market
figur pharma market expect grow mid-singl digit
return market growth pharma start report organ pharma
sale grown market last seven consecut quarter expect growth slow
dip market come quarter due impact gener zytiga tracleer
biosimilar remicade/procrit estim jnj pharma sale grow organ
acceler histor jnj organ pharma sale growth in-lin
market recent year adjust basi exclud prior period price adjust
differ sell day impact hep-c franchis estim growth least
high-singl digit past year figur call manag state
patient loss zytiga tracleer anniversari compani even
stronger pharma organ back well pharma market growth
figur pharma expect return above-market growth
ep growth also acceler forecast ep in-lin
consensu near high-end guidanc rang ep estim
yr/yr consensu forecast anticip declin net incom
half model pose headwind ep growth manag commentari call
suggest combin sale growth acceler cost improv initi margin
improv suffici provid off-set deliv consist earn growth
 pharma pharma factset large-cap pharma except well fargo secur llc estim sale cagrconsensu sale mm organ organ pharma median report adjust fx acquisitions/divestitur adjust us sell day differ hep-c franchis disclos prior period price adjust ppa factset large-cap pharma except well fargo secur llc estim sale cagryr/yr sale growthsal cagrsales/growth medic technolog
expect blockbust portfolio product remain larg unchang pharma day
highlight blockbust product sale includ mega-brand
sale figur anticip product remain blockbust categori see
invokana remov list place could see tremfya psoriasi ad
blockbust list less year market estim tremfya sale approach
year pharma day year expect manag highlight blockbust
opportun especi mega-brand discuss growth momentum continu
blockbust opportun pipelin shrunk bit addit product
current blockbust statu also expect emphas key recent new product launch key
one would highlight spravato treatment-resist depress trd erleada prostat
cancer balversa bladder cancer spravato understand kol key
opinion leader speak pharma day three product among jnj pipelin
product sale potenti howev sever product may blockbust
pipelin list figur longer includ sirukumab psoriasi fda requir addit trial
approv talacotuzumab aml acut myeloid leukemia imetelstat myelofibrosi
termin deal addit phase develop lumicitabin rsv respiratori
syncyti viru alio acquisit put hold asset monitor
impair given number chang pipelin potenti blockbust look
highlight addit mid- late-stag pipelin product take place
bullish consensu jnj pharma portfolio pharma sale forecast
exce consensu expect year figur differ
increas year forecast exceed consensu
five key product bullish consensu darzalex stelara invega
sustenna/trinza franchis imbruvica prezista franchis aggreg estim five drug
account less jnj total pharma revenu expect revenu contribut
exceed beyond discuss product explain forecast
consensu estim estim appear bullish consensu mani product
also point consensu forecast individu product gener consist
analyst estim analyst actual cover consensu estim
product may reflect true market expect
figur vs consensu forecast drug
darzalex ww darzalex sale estim well consensu forecast
dont think number unreason see drug strong growth momentum
continu base move front-lin therapi multipl myeloma new indic formul
 subq anticip durat ip protect expect maia approv us
would propel darzalex front-lin use help establish drug part backbon
treatment multipl myeloma anticip approv new subq formul
meaning expand patient access drug drive continu growth recal subq
formul significantli reduc infus time hour minut increas
patient capac treatment center ip front key composit matter patent expir
includ patent term extens us major eu market
analyst day partner genmab manag forecast darzalex sale grow year
reach figur genmab also estim end-us darzalex sale aggreg
current forecast total ww sale consensu estim
period current genmab consensu forecast total darzalex royalti
consist genmab manag expect
sale wf estim compani report factset secur llc cagrour estimate vs consensu neg consensu higher medic technolog
stelara forecast ww stelara sale grow compound-annual-growth-rate
period consensu forecast nearli compound-annual-growth-rate key
composit matter patent expir late us earli europ
eros sale time would attribut cannib jnj tremfya
like skyrizi like cosentyx taltz howev recent like futur growth stelara
primarili driven non-psoriasi indic crohn crohn approv late
account one-third share prescript stelara base write stelara
prescript despit entri cosentyx taltz tremfya stelara sale
growth momentum continu larg driven uptak
crohn expect approv ulcer coliti uc later crohn uc two type
inflammatori bowel diseas ibd similar symptom howev crohn mix
healthi inflam area intestin wherea uc continu inflamm colon
addit uc affect colon crohn occur anywher digest tract
addit evalu stelara lupu recent enter phase studi complet
expect phase studi show significantli higher proport patient take
stelara show improv lupu diseas activ vs patient placebo group vs
respect lupu repres signific unmet medic need could support stelara
growth success expect stelara sale growth slow time believ
growth new indic may underappreci street
sale compound-annual-growth-rate compar consensu assumpt declin
period forecast assum gener competit period due drug complex
manufactur even though key patent market exclus expir jnj
manufactur patent challeng although trial date set yet stay
associ sustenna patent challeng end assum
complex manufactur prevent gener competit time
addit develop formul invega sustenna monthli trinza everi
month new formul phase develop expect complet juli
launch invega sustenna nearli year ago invega trinza follow trevicta eu
sale two product grew introduct
month formul help continu invega franchis sale growth albeit slower pace
pharma day note paliperidon potenti offer greater
protect relaps studi show prolong dose interv lead longer relapse-fre
period compet long-act inject antipsychot laia gain share slowli
abilifi trx share aristada trx share nearli jnj risperd
consta continu see share eros invega sustenna/trinza franchis seen
rel steadi volum share past coupl year accord im sustenna continu
account nearli franchis sale
imbruvica forecast ww imbruvica revenu grow
consensu estim respect above-consensu imbruvica
estim base continu growth driven addit indic although estim
optimist compar consensu beyond believ direct consist
assum record us end-us sale plu ou sale
record ou end-us sale plu abbv us sale appli split imbruvica
revenu forecast translat ww end-us imbruvica sale grow
math translat imbruvica revenu
larg consist analyst estim imbruvica
acquir pharmacycl compani forecast peak imbruvica revenu
primarili driven growth exist indic move earlier line treatment
expans addit b-cell malign call discuss transact
manag commentari suggest peak end-us sale probabl reason
imbruvica key composit matter patent expir end us beyond
major eu market although patent challeng underway us sinc late note
com patent gener difficult overcom gener assum gener competit
stay expir
prezista hiv franchis forecast ww prezista/prezcobix/symtuza sale grow
peak follow declin due prezista gener competit
forecast impli sale compound-annual-growth-rate consensu forecast
declin period model assum us gener prezista
darunavir competit start base time settlement believ
gener settlement well known thu reflect consensu forecast howev
note on-going prezista patent litig includ one vs rdi trial date may
howev may under-appreci darunavir-bas hiv franchis consist fix dose
combin product like prezcobix darunavir cobicistat recent symtuza darunavir
cobicistat emtricitabin taf tenofovir alafenamid accord us im data prezcobix account
nearli franchis new prescript nrx symtuza repres nearli franchis
nrx less year market expect symtuza contribut increas time
gener prezista arriv mean impact gener prezista modest
like cannib within franchis symtuza seen jnj overal darunavir
franchis sale grow follow prezcobix launch believ stay power
hiv franchis beyond prezista
talc litig updat daubert hear come juli want highlight upcom
daubert motion hear schedul late juli ovarian cancer link talc powder lawsuit
judg expect decid whether plaintiff reliabl scientif proof regard talc-ovarian
cancer link rais daubert motion exclud plaintiff expert testimoni trial
accord compani plaintiff expert often reli data gener retrospect interview
women habit involv talc powder case-control methodolog convers
compani believ type interview may gener bias data thu
repres scientif proof cite larger prospect studi interview women
talc routin follow women cours decad could court rule
could determin case move forward
accord jnj recent case pend relat talc-contain bodi powder
understand major ovarian cancer case far success
mani talc litig high-profil loss ovarian-canc link talc litig
juri award punit compensatori women st loui juli
appeal decis preced larg product liabil case suggest
reward like reduc figur
continu view talc litig manag given vast resourc exampl even
talc case settl per case highest per case settlement amount among
case weve track figur total liabil would even assum
current number case doubl next year use per case
settlement assumpt translat total liabil cash market
secur end addit signific cash posit borrow power note
insur may respons least partial pay final damag case
figur largest product liabil award us juri
figur prior major drug devic product liabil settlement
price target
price target impli cash ep base sum-of-the-part
analysi risk includ delay pipelin product unexpect delay deal integr unexpect
deterior industri
expect growth slow due multipl headwind see growth re-acceler
johnson johnson world comprehens broadli base healthcar compani
consum pharmaceut medic devic market medic devic segment consist primarili
product cardiovascular orthoped surgic vision compani report sale
year-over-year organ basi
caseiniti awardpost-verdict resultengl reynold philip morri reynold johnson johnson pendingboeken philip morri depuy orthoped johnson kart wyeth texa bloomberg secur llcest total patientssettlementsettl costsettl costlitigationcompanypati claimcost mm per claim per patient compani report new york time wall street journal diet drug settlement websit secur llc johnson johnson
